Key takeaway: Sakar Healthcare Limited reported on its Q1 FY27 earnings during the analyst call held on July 29, 2026. Management highlighted a strong operational and financial performance, with revenue from operations reaching INR 7,297 lakhs, a year-on-year growth of 38%. EBITDA increased by 67% to INR 2,125 lakhs, and profit after tax grew by 120% to INR 1,028 lakhs. The company emphasized its focus on building a robust oncology business, having executed over 65 oncology product contracts and submitted 261 oncology dossiers globally. Management noted the importance of market access and reported 16 marketing authorizations received during the quarter. The integrated EU-GMP approved oncology facility at Bavla is central to their export strategy, with potential revenues projected between INR 800 crores to INR 1,000 crores at optimal utilization over the next 4 to 5 years. Management expressed confidence in the growth of their oncology exports and the overall business.

Key takeaway: On July 28, 2026, Sakar Healthcare Limited submitted an investor presentation detailing its un-audited financial results for the quarter ended June 30, 2026. The presentation highlighted a 38% year-on-year increase in revenue from operations, reaching ₹7,297 lakhs, driven by new market authorizations in oncology and strong demand. EBITDA rose by 67% to ₹2,125 lakhs, with a margin of 29%. Profit after tax (PAT) also saw significant growth, increasing by 120% to ₹1,028 lakhs, reflecting improved operational efficiencies. The company reported ongoing expansion in its oncology business, with over 65 product contracts executed and a growing pipeline of regulatory approvals. Sakar is transitioning to a more integrated business model, enhancing its operational capabilities and market presence in the oncology sector.

Key takeaway: During the earnings call for Q4 FY26, management reported significant growth in Sakar Healthcare Limited's financial performance, with a 42% year-on-year increase in revenue from operations, reaching INR7,109.70 lakhs. EBITDA rose by 67% to INR2,623.57 lakhs, resulting in EBITDA margins of 37%. The oncology division contributed approximately 38% of total revenues, marking a shift towards a more focused oncology business model. Management highlighted the successful establishment of an oncology platform, with over 60 contracts signed and ongoing discussions with various partners. The company aims to achieve over 300 dossier approvals and more than 100 overseas business contracts in the next two years. Management also noted that the scalability of their oncology facility could generate revenues of INR800 crores to INR1,000 crores at optimal utilization. Overall, the call emphasized the positive trajectory of the company's oncology business and its strategic focus on exports.

Key takeaway: Sakar Healthcare Limited submitted an investor presentation detailing its audited financial results for the quarter and year ended March 31, 2026. The presentation highlighted a 42% year-over-year revenue increase to ₹7,110 lakhs, driven by growth in the oncology sector and new market authorizations. EBITDA rose 67% to ₹2,624 lakhs, with an EBITDA margin of 37%. The company reported a PAT margin of 16%, indicating improved earnings quality. Sakar's oncology business is positioned as a key growth driver, with ongoing approvals and launches. The company completed over 60 business contracts related to oncology products and shared 250 dossiers globally, with 12 receiving marketing authorizations. The presentation emphasized Sakar's commitment to sustainable operations and its integrated API and FDF manufacturing capabilities, particularly in oncology.

Key takeaway: Sakar Healthcare Limited held its Q3 FY26 earnings conference call on February 11, 2026, where management reported strong operational momentum and growth across key metrics. The oncology vertical showed significant traction, with the EU GMP approved facility in Bavla gaining strategic relevance globally. Management highlighted the approval of the oncology facility for EU product supplies as a major milestone. Financially, Q3 FY26 revenue from operations reached INR 7,034 lakhs, a 62% year-on-year increase, while EBITDA rose to INR 1,859 lakhs, reflecting a 58% growth. Profit after tax also saw a substantial increase of 126% year-on-year. Management noted that over 70% of revenue now comes from high-margin own brand exports. The call concluded with management expressing gratitude to stakeholders and emphasizing the company's commitment to sustainable practices and long-term value creation.

Key takeaway: On February 10, 2026, Sakar Healthcare Limited submitted an investor presentation detailing its unaudited financial results for the quarter and nine months ended December 31, 2025. The presentation highlighted a significant 62% year-over-year revenue growth to INR 7,034 lakhs, driven by new market authorizations in oncology products. EBITDA also increased by 58% year-over-year, reaching INR 1,859 lakhs, with a margin of 26%. The company reported a profit after tax (PAT) of INR 1,025 lakhs, reflecting a 126% increase compared to the previous year. Sakar's oncology facility received approval as a manufacturing source for Accord Healthcare UK, enhancing its export pipeline. The presentation emphasized the company's strategic focus on oncology, with 55 oncology molecules developed and 32 dossiers ready for launch, positioning Sakar for future growth in this sector.